| Symbol | TNGX |
|---|---|
| Name | TANGO THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 201 BROOKLINE AVE.,SUITE 901, BOSTON, Massachusetts, 02215, United States |
| Telephone | +1 857 320-4900 |
| Fax | — |
| — | |
| Website | https://www.tangotx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001819133 |
| Description | Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Additional info from NASDAQ: |
2026-07-02 23:23
Crystal Adam 🟡 adjusted position in 27.0K shares (1 derivative) of Tango Therapeutics, Inc. (TNGX) at $30.25 ($1.1M) Transaction Date: Jul 01, 2026 | Filing ID: 295124
Read more
2026-06-23 22:10
Azelby Robert 🟢 acquired 41.6K shares (1 derivative) of Tango Therapeutics, Inc. (TNGX) at $27.97 ($1.0M) Transaction Date: Jun 19, 2026 | Filing ID: 279871
Read more
2026-06-23 21:19
(99% Positive) TANGO THERAPEUTICS, INC. (TNGX) Provides Update on care for oncology commercialization
Read more
2026-06-23 19:04
New Form 3 - Tango Therapeutics, Inc. <b>Filed:</b> 2026-06-23 <b>AccNo:</b> 0001193125-26-279866 <b>Size:</b> 16 KB
Read more
2026-06-17 20:45
📋 Nextech Crossover I SCSp (Ex-Affiliate) plans to sell 3.8M shares of TANGO THERAPEUTICS, INC. (at $30.10 each, total $113.4M) Filed: Jun 17, 2026 | ID: 000002
Read more
2026-06-11 22:00
📋 DANIELLA BECKMAN (Officer) plans to sell 1.8M shares of TANGO THERAPEUTICS, INC. (at $28.76 each, total $51.5M) Filed: Jun 11, 2026 | ID: 005968
Read more
2026-06-10 21:22
(99% Neutral) TANGO THERAPEUTICS, INC. (TNGX) Announces Business Combination
Read more
2026-06-10 20:45
📋 DANIELLA BECKMAN (Officer) plans to sell 4K shares of TANGO THERAPEUTICS, INC. (at $30.00 each, total $133K) Filed: Jun 10, 2026 | ID: 005901
Read more
2026-06-10 18:21
New Form 424B5 - Tango Therapeutics, Inc. <b>Filed:</b> 2026-06-10 <b>AccNo:</b> 0001193125-26-266074 <b>Size:</b> 836 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06922591 | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination … | Phase1 | PDAC | Recruiting | 2025-05-31 | 2027-12-01 | ClinicalTrials.gov |
| NCT06810544 | Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in … | Phase1 | Non Small Cell Lung Cancer | Recruiting | 2025-03-24 | 2027-09-30 | ClinicalTrials.gov |
| NCT06065059 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA … | Phase1 | Breast Cancer | Terminated | 2023-12-08 | 2024-05-22 | ClinicalTrials.gov |
| NCT05887492 | Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors | Phase1 | Non Small Cell Lung Cancer | Active_Not_Recruiting | 2023-06-12 | 2026-09-01 | ClinicalTrials.gov |
| NCT05732831 | Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors | Phase1 | Locally Advanced Solid Tumor | Recruiting | 2023-05-26 | 2026-09-01 | ClinicalTrials.gov |
| NCT05275478 | Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors | Phase1 | Locally Advanced Solid Tumor | Terminated | 2022-03-23 | 2025-12-30 | ClinicalTrials.gov |
Total clinical trials: 6
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Pembrolizumab | Other | Phase PHASE1 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05887492 |
| TNG260 | Other | Phase PHASE1 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05887492 |
| gemcitabine/nab-paclitaxel | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| mFOLFIRINOX | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-6236 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-9805 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| TNG462 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| gemcitabine/nab-paclitaxel | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| mFOLFIRINOX | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-6236 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-9805 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| TNG462 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| gemcitabine/nab-paclitaxel | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| mFOLFIRINOX | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-6236 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-9805 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| TNG462 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| gemcitabine/nab-paclitaxel | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| mFOLFIRINOX | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-6236 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-9805 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| TNG462 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| gemcitabine/nab-paclitaxel | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| mFOLFIRINOX | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-6236 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-9805 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| TNG462 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| gemcitabine/nab-paclitaxel | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| mFOLFIRINOX | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-6236 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-9805 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| TNG462 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| gemcitabine/nab-paclitaxel | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| mFOLFIRINOX | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-6236 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-9805 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| TNG462 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| gemcitabine/nab-paclitaxel | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| mFOLFIRINOX | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-6236 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-9805 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| TNG462 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| Olaparib | Other | Phase PHASE1 | Breast Cancer | TERMINATED | NCT06065059 |
| TNG348 | Other | Phase PHASE1 | Breast Cancer | TERMINATED | NCT06065059 |
| Pembrolizumab | Other | Phase PHASE1 | Non Small Cell Lung Cancer | RECRUITING | NCT05887492 |
| TNG260 | Other | Phase PHASE1 | Non Small Cell Lung Cancer | RECRUITING | NCT05887492 |
| abemaciclib | Other | Phase PHASE1 | Non Small Cell Lung Cancer | RECRUITING | NCT06810544 |
| TNG456 | Other | Phase PHASE1 | Non Small Cell Lung Cancer | RECRUITING | NCT06810544 |
| TNG908 | Other | Phase PHASE1 | Locally Advanced Solid Tumor | TERMINATED | NCT05275478 |
| Pembrolizumab | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05732831 |
| TNG462 | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05732831 |
| gemcitabine/nab-paclitaxel | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| mFOLFIRINOX | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-6236 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-9805 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| TNG462 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| gemcitabine/nab-paclitaxel | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| mFOLFIRINOX | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-6236 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-9805 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| TNG462 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| gemcitabine/nab-paclitaxel | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| mFOLFIRINOX | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-6236 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-9805 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| TNG462 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| gemcitabine/nab-paclitaxel | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| mFOLFIRINOX | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-6236 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-9805 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| TNG462 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| gemcitabine/nab-paclitaxel | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| mFOLFIRINOX | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-6236 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-9805 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| TNG462 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| gemcitabine/nab-paclitaxel | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| mFOLFIRINOX | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-6236 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-9805 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| TNG462 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| gemcitabine/nab-paclitaxel | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| mFOLFIRINOX | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-6236 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-9805 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| TNG462 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| gemcitabine/nab-paclitaxel | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| mFOLFIRINOX | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-6236 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-9805 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| TNG462 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| Pembrolizumab | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05732831 |
| TNG462 | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05732831 |
| gemcitabine/nab-paclitaxel | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| mFOLFIRINOX | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-6236 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-9805 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| TNG462 | Other | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| Pembrolizumab | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05732831 |
| TNG462 | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05732831 |
| Pembrolizumab | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05732831 |
| TNG462 | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05732831 |
| Pembrolizumab | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05732831 |
| TNG462 | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05732831 |
| Pembrolizumab | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05732831 |
| TNG462 | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05732831 |
| Pembrolizumab | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05732831 |
| TNG462 | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05732831 |
| Pembrolizumab | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05732831 |
| TNG462 | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05732831 |
| gemcitabine/nab-paclitaxel | DRUG | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| mFOLFIRINOX | DRUG | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-6236 | DRUG | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| RMC-9805 | DRUG | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| abemaciclib | DRUG | Phase PHASE1 | Non Small Cell Lung Cancer | RECRUITING | NCT06810544 |
| TNG456 | DRUG | Phase PHASE1 | Non Small Cell Lung Cancer | RECRUITING | NCT06810544 |
| S095035 | DRUG | Phase PHASE1 | MTAP-deleted Solid Tumors | RECRUITING | NCT06188702 |
| Olaparib | DRUG | Phase PHASE1 | Breast Cancer | TERMINATED | NCT06065059 |
| TNG348 | DRUG | Phase PHASE1 | Breast Cancer | TERMINATED | NCT06065059 |
| TNG260 | DRUG | Phase PHASE1 | Non Small Cell Lung Cancer | RECRUITING | NCT05887492 |
| Pembrolizumab | DRUG | Phase PHASE1 | Non Small Cell Lung Cancer | RECRUITING | NCT05887492 |
| TNG462 | DRUG | Phase PHASE1 | PDAC | RECRUITING | NCT06922591 |
| TNG908 | DRUG | Phase PHASE1 | Locally Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05275478 |
Total products: 123